The Multiple Sclerosis Society has welcomed the results of the phase II double-blind, placebo-controlled trial of the monoclonal antibody Antegren (natalizumab) including 213 people with MS at 26 sites in the UK, USA and Canada. The results are published in the New England Journal of Medicine of Thursday 2 January 2003.
Mike O'Donovan, chief executive of the Society, said, "The results show significant reduction in MS brain lesions and the number of relapses or attacks people experienced. They look very promising and we hope the Phase III studies now in progress will confirm the potential of another treatment to help control the symptoms of this devastating disease.
The Society is pleased to be contributing to the trials through its long-term funding of the MS magnetic resonance imaging (MRI) unit at the National Hospital for Neurology in Queen Square, London, where much of the lesion data is being analysed. This is the only MRI unit in the world dedicated entirely to work on multiple sclerosis."